Endourage
June 16, 2025
Company Presentation
Platform for Therapeutics
Endourage is developing novel therapeutics for Chronic Disease. The company is preparing to bring its platform of 11 therapeutics, all developed in humans and with human clinical data into the FDA's botanical drug path.
Our lead product is for Long COVID which impacts 10M Americans. We successfully completed an IRB-approved, US based, human clinical trial where successfully attenuated 8 of the 9 most common Long COVID symptoms and improved Patient quality of life 200%. The results of the trial we published in a peer-reviewed medical journal as was our theory on treating both acute and chronic COVID.
Company HQ City:
Wheat RIdge
Company HQ State:
CO
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Formula C for Long COVID. Has already successfully been test in a human, US-based, IRB-approved human clinical trial where we successfully attenuated 8 of the 9 most common symptoms of Long COVID.
CEO
Isaac Foster
Year Founded
2018
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
12
When you expect your next catalyst update?
Getting our lead product into Clinicals
What is your next catalyst (value inflection) update?
Within 6 months of our next funding round.
Website
endourage.com
Primary Speaker
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}